SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                -----------------

                                    Form 8-K

                                 CURRENT REPORT
                       PURSUANT TO SECTION 13 OR 15(d) OF
                       THE SECURITIES EXCHANGE ACT OF 1934


        Date of Report (Date of earliest event reported): March 28, 2002


                                  XTRANA, INC.
               (Exact Name of Registrant as Specified in Charter)


      Delaware                      0-17714                    58-1729436
(State or Other Jurisdiction      (Commission               (IRS Employer
   of Incorporation)               File Number)              Identification No.)


                          590 Burbank Street, Suite 205
                           Broomfield, Colorado 80020
                    (Address of Principal Executive Offices)

                                 (303) 466-4424
                         (Registrant's Telephone Number)


                                       1


<PAGE>


ITEM 5.  OTHER EVENTS

         Reference  is  made  to  the  press   release  of  Xtrana,   Inc.  (the
"Registrant"),  issued on March 28, 2002,  announcing  2001  year-end and fourth
quarter results. A copy of the press release, which contains information meeting
the  requirements of this Item 5, is attached to this Form 8-K as Exhibit 99 and
is incorporated herein by this reference.


ITEM 7.  FINANCIAL STATEMENTS AND EXHIBITS

(a)      Financial Statements.  None.

(b)      Pro Forma Financial Information.  None.

(c)      Exhibits.

         Exhibit 99      Press Release of the  Registrant  dated March 28, 2002,
                         announcing  2001 year-end and fourth quarter results.


                                   SIGNATURES


         Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
the  Registrant  has duly  caused  this report to be signed on its behalf by the
undersigned hereunto duly authorized.


April 4, 2002                              XTRANA, INC.



                                           By:  /S/ TIMOTHY DAHLTORP
                                               -------------------------------
                                                Timothy Dahltorp
                                                Chief Executive Officer
                                                Chief Financial Officer


                                       2


<PAGE>




                                  EXHIBIT INDEX

Exhibit                                                              Page Number

    99     Press Release of the Registrant dated March 28, 2002,            4
           announcing 2001 year-end and fourth quarter results.




                                       3


<PAGE>


                                   EXHIBIT 99

PRESS RELEASE

                              XTRANA, INC. REPORTS
                    2001 YEAR-END AND FOURTH QUARTER RESULTS

Broomfield, Colorado (March 28, 2002) - Xtrana, Inc. (OTCBB:XTRN) today reported
results for the year and fourth  quarter ended December 31, 2001. The results of
operations  for the current and prior  periods have been restated to reflect the
sale of the  Hemostasis  operations  of the Company on December  21,  2001.  The
results  of  the  sold  operations   have  been   reclassified  as  discontinued
operations.
         2001  sales  from  continuing  operations  increased  313%  percent  to
$479,000  from  $116,000  in  2000.  The  Company  also  reported  a net loss of
$2,856,000,  or $0.17 per share,  in 2001  versus a net loss of  $1,109,000,  or
$0.09 per  share,  for the  previous  year.  In 2001,  the loss from  continuing
operations before taxes was $4,091,000 compared with a net loss of $1,723,000 in
2000.
         Fourth quarter sales from continuing  operations increased 185% percent
to $202,000 in 2001 from $71,000 in 2000. A net loss from continuing  operations
of $1,103,000,  or $0.06 per share, was reported in fourth quarter 2001 versus a
net loss of $917,000, or $0.05 per share, for the same period a year ago.
         "During 2001, the Company completed a significant  transformation  that
was begun  with the merger in August of 2000 with  Xtrana.  With the sale of our
Hemostasis  operations late last year,  Xtrana is now completely  focused on the
commercialization  of our  nucleic  acid  products  and  technologies.  The  net
consideration  of cash and notes,  which we received in that sale, was just over
$6 million.  This inflow of capital  was  critical as it gives us the  financial
support necessary to help us complete the  commercialization of our nucleic acid
products  and  technologies,"  commented  Timothy J.  Dahltorp,  Xtrana's  chief
executive officer.
         "We are very pleased to report a $131,000,  or 185%,  increase in sales
from our  continuing  operations  for the last  quarter of 2001  versus the same
period in 2000," Mr. Dahltorp continued, "which was the result of an increase in
research grant revenue and sales of our Xtra Amp(TM) DNA extraction  kits.  This
increase  in  revenue  helped to reduce  our cash burn rate  during  the  fourth
quarter.  The  cash  loss  (earnings  before  interest,   taxes,   depreciation,
amortization  and other  non-cash  charges) from our  continuing  operations was
$2,870,000 for the year and $677,000 for the fourth quarter. This revenue growth
is a trend that we hope to see  continue  in  subsequent  quarters as we achieve
further  market  penetration  with our Xtra Amp(TM)  products.  The Xtra Amp(TM)
kits,  although  early in their  market  introduction,  are  being  accepted  by
researchers  due to their  simplicity  and speed,  and we are  beginning  to see
re-orders of the kits from both  distributors  and end users. The next year is a
critical  one for Xtrana,  as we strive to develop  Xtra Amp(TM) into a reliable
and growing source of revenue,  while at the same time advancing the development
of our diagnostic applications."


                                       4


<PAGE>


         Xtrana's  mission is to  simplify  the  analysis  of  DNA/RNA,  so that
nucleic   acid-based   detection  systems  can  be  utilized  in  point-of-care,
point-of-service  applications.  The proprietary  assays developed by Xtrana are
designed to be easy to use outside of a traditional molecular biology laboratory
at a cost per test that is competitive  with existing  rapid test  technologies.
These  diagnostic  tests are  intended for use in drug  discovery,  detection of
environmental and food contaminants,  forensics and identity testing,  human and
animal diseases,  genetic predisposition to disease, and other applications.  To
learn more about Xtrana, visit the Company's website at www.xtrana.com.


This Press Release contains forward-looking  statements (identified by the words
"estimate,"  "anticipate," "expect," "believe," and similar expressions),  which
are based upon management's  current  expectations and speak only as of the date
made. These forward-looking  statements are subject to risks,  uncertainties and
factors that could cause actual  results to differ  materially  from the results
anticipated in the forward-looking  statements and include,  but are not limited
to, competitors'  pricing strategies and technological  innovations,  changes in
health care and government  regulations,  litigation  claims,  foreign  currency
fluctuation,  product  acceptance,  as well as other  factors  discussed  in the
Company's last Report on Form 10-KSB.



                            (Financial Tables Follow)


                                       5


<PAGE>


                                  XTRANA, INC.
                            2001 FINANCIAL HIGHLIGHTS
                        (in thousands except share data)


                                 OPERATIONS DATA
                                   (UNAUDITED)


                                    THREE MONTHS ENDED           YEAR ENDED
                                   --------------------    --------------------
DECEMBER 31                            2001        2000        2001        2000
-----------                        --------    --------    --------    --------

Sales ..........................   $    202    $     71    $    479    $    116

Income (loss) from continuing
   operations before taxes .....     (1,103)       (917)     (4,091)     (1,723)

Net income (loss) ..............       (114)     (1,538)     (2,856)     (1,109)

Basic and diluted earnings
per share, net of taxes:

   Continuing operations .......   $  (0.06)   $  (0.05)   $  (0.24)   $  (0.14)

   Net income (loss) ...........   $  (0.01)   $  (0.09)   $  (0.17)   $  (0.09)

Diluted shares outstanding .....     17,315      17,162      17,219      11,842



                               BALANCE SHEET DATA
                                   (UNAUDITED)


DECEMBER 31,                                               2001             2000
------------                                            -------          -------

Working capital ..............................          $ 3,940          $ 7,727

Total assets .................................           15,913           17,871

Long-term debt ...............................             --               --

Total shareholders' equity ...................           15,068           17,260



                                      # # #

Contact:
     Xtrana, Inc.
     Timothy Dahltorp, 303/466-3326


                                       6
[{"type": "8-K", "sequence": "1", "filename": "xtrn8k032802.txt", "description": "8-K DATED 3/28/2002", "secsgml_size_bytes": 9641}]
{"company-data": {"conformed-name": "XTRANA INC", "cik": "0000830736", "assigned-sic": "2835", "irs-number": "581729436", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-14257", "film-number": "02602233"}, "business-address": {"street1": "590 BURBANK STREET", "street2": "SUITE 205", "city": "BROOMFIELD", "state": "CO", "zip": "80020", "phone": "3034664424"}, "mail-address": {"street1": "590 BURBANK STREET", "street2": "SUITE 205", "city": "BROOMFIELD", "state": "CO", "zip": "80020"}, "former-company": [{"former-conformed-name": "CYTRX BIOPOOL LTD", "date-changed": "19890716"}, {"former-conformed-name": "BIOPOOL INTERNATIONAL INC", "date-changed": "19920703"}]}
SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                -----------------

                                    Form 8-K

                                 CURRENT REPORT
                       PURSUANT TO SECTION 13 OR 15(d) OF
                       THE SECURITIES EXCHANGE ACT OF 1934

        Date of Report (Date of earliest event reported): March 28, 2002

                                  XTRANA, INC.
               (Exact Name of Registrant as Specified in Charter)

      Delaware                      0-17714                    58-1729436
(State or Other Jurisdiction      (Commission               (IRS Employer
   of Incorporation)               File Number)              Identification No.)

                          590 Burbank Street, Suite 205
                           Broomfield, Colorado 80020
                    (Address of Principal Executive Offices)

                                 (303) 466-4424
                         (Registrant's Telephone Number)

                                       1
ITEM 5.  OTHER EVENTS

         Reference  is  made  to  the  press   release  of  Xtrana,   Inc.  (the
"Registrant"),  issued on March 28, 2002,  announcing  2001  year-end and fourth
quarter results. A copy of the press release, which contains information meeting
the  requirements of this Item 5, is attached to this Form 8-K as Exhibit 99 and
is incorporated herein by this reference.

ITEM 7.  FINANCIAL STATEMENTS AND EXHIBITS

(a)      Financial Statements.  None.

(b)      Pro Forma Financial Information.  None.

(c)      Exhibits.

         Exhibit 99      Press Release of the  Registrant  dated March 28, 2002,
                         announcing  2001 year-end and fourth quarter results.

                                   SIGNATURES

         Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
the  Registrant  has duly  caused  this report to be signed on its behalf by the
undersigned hereunto duly authorized.

April 4, 2002                              XTRANA, INC.

                                           By:  /S/ TIMOTHY DAHLTORP
                                               -------------------------------
                                                Timothy Dahltorp
                                                Chief Executive Officer
                                                Chief Financial Officer

                                       2
EXHIBIT INDEX

Exhibit                                                              Page Number

    99     Press Release of the Registrant dated March 28, 2002,            4
           announcing 2001 year-end and fourth quarter results.

                                       3
EXHIBIT 99

PRESS RELEASE

                              XTRANA, INC. REPORTS
                    2001 YEAR-END AND FOURTH QUARTER RESULTS

Broomfield, Colorado (March 28, 2002) - Xtrana, Inc. (OTCBB:XTRN) today reported
results for the year and fourth  quarter ended December 31, 2001. The results of
operations  for the current and prior  periods have been restated to reflect the
sale of the  Hemostasis  operations  of the Company on December  21,  2001.  The
results  of  the  sold  operations   have  been   reclassified  as  discontinued
operations.
         2001  sales  from  continuing  operations  increased  313%  percent  to
$479,000  from  $116,000  in  2000.  The  Company  also  reported  a net loss of
$2,856,000,  or $0.17 per share,  in 2001  versus a net loss of  $1,109,000,  or
$0.09 per  share,  for the  previous  year.  In 2001,  the loss from  continuing
operations before taxes was $4,091,000 compared with a net loss of $1,723,000 in
2000.
         Fourth quarter sales from continuing  operations increased 185% percent
to $202,000 in 2001 from $71,000 in 2000. A net loss from continuing  operations
of $1,103,000,  or $0.06 per share, was reported in fourth quarter 2001 versus a
net loss of $917,000, or $0.05 per share, for the same period a year ago.
         "During 2001, the Company completed a significant  transformation  that
was begun  with the merger in August of 2000 with  Xtrana.  With the sale of our
Hemostasis  operations late last year,  Xtrana is now completely  focused on the
commercialization  of our  nucleic  acid  products  and  technologies.  The  net
consideration  of cash and notes,  which we received in that sale, was just over
$6 million.  This inflow of capital  was  critical as it gives us the  financial
support necessary to help us complete the  commercialization of our nucleic acid
products  and  technologies,"  commented  Timothy J.  Dahltorp,  Xtrana's  chief
executive officer.
         "We are very pleased to report a $131,000,  or 185%,  increase in sales
from our  continuing  operations  for the last  quarter of 2001  versus the same
period in 2000," Mr. Dahltorp continued, "which was the result of an increase in
research grant revenue and sales of our Xtra Amp(TM) DNA extraction  kits.  This
increase  in  revenue  helped to reduce  our cash burn rate  during  the  fourth
quarter.  The  cash  loss  (earnings  before  interest,   taxes,   depreciation,
amortization  and other  non-cash  charges) from our  continuing  operations was
$2,870,000 for the year and $677,000 for the fourth quarter. This revenue growth
is a trend that we hope to see  continue  in  subsequent  quarters as we achieve
further  market  penetration  with our Xtra Amp(TM)  products.  The Xtra Amp(TM)
kits,  although  early in their  market  introduction,  are  being  accepted  by
researchers  due to their  simplicity  and speed,  and we are  beginning  to see
re-orders of the kits from both  distributors  and end users. The next year is a
critical  one for Xtrana,  as we strive to develop  Xtra Amp(TM) into a reliable
and growing source of revenue,  while at the same time advancing the development
of our diagnostic applications."

                                       4
Xtrana's  mission is to  simplify  the  analysis  of  DNA/RNA,  so that
nucleic   acid-based   detection  systems  can  be  utilized  in  point-of-care,
point-of-service  applications.  The proprietary  assays developed by Xtrana are
designed to be easy to use outside of a traditional molecular biology laboratory
at a cost per test that is competitive  with existing  rapid test  technologies.
These  diagnostic  tests are  intended for use in drug  discovery,  detection of
environmental and food contaminants,  forensics and identity testing,  human and
animal diseases,  genetic predisposition to disease, and other applications.  To
learn more about Xtrana, visit the Company's website at www.xtrana.com.

This Press Release contains forward-looking  statements (identified by the words
"estimate,"  "anticipate," "expect," "believe," and similar expressions),  which
are based upon management's  current  expectations and speak only as of the date
made. These forward-looking  statements are subject to risks,  uncertainties and
factors that could cause actual  results to differ  materially  from the results
anticipated in the forward-looking  statements and include,  but are not limited
to, competitors'  pricing strategies and technological  innovations,  changes in
health care and government  regulations,  litigation  claims,  foreign  currency
fluctuation,  product  acceptance,  as well as other  factors  discussed  in the
Company's last Report on Form 10-KSB.

                            (Financial Tables Follow)

                                       5
XTRANA, INC.
                            2001 FINANCIAL HIGHLIGHTS
                        (in thousands except share data)

                                 OPERATIONS DATA
                                   (UNAUDITED)

                                    THREE MONTHS ENDED           YEAR ENDED
                                   --------------------    --------------------
DECEMBER 31                            2001        2000        2001        2000
-----------                        --------    --------    --------    --------

Sales ..........................   $    202    $     71    $    479    $    116

Income (loss) from continuing
   operations before taxes .....     (1,103)       (917)     (4,091)     (1,723)

Net income (loss) ..............       (114)     (1,538)     (2,856)     (1,109)

Basic and diluted earnings
per share, net of taxes:

   Continuing operations .......   $  (0.06)   $  (0.05)   $  (0.24)   $  (0.14)

   Net income (loss) ...........   $  (0.01)   $  (0.09)   $  (0.17)   $  (0.09)

Diluted shares outstanding .....     17,315      17,162      17,219      11,842

                               BALANCE SHEET DATA
                                   (UNAUDITED)

DECEMBER 31,                                               2001             2000
------------                                            -------          -------

Working capital ..............................          $ 3,940          $ 7,727

Total assets .................................           15,913           17,871

Long-term debt ...............................             --               --

Total shareholders' equity ...................           15,068           17,260

                                      # # #

Contact:
     Xtrana, Inc.
     Timothy Dahltorp, 303/466-3326

                                       6